NASDAQ:NCEL NLS Pharmaceutics (NCEL) Stock Price, News & Analysis $3.81 -0.16 (-4.03%) As of 07/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About NLS Pharmaceutics Stock (NASDAQ:NCEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NLS Pharmaceutics alerts:Sign Up Key Stats Today's Range$3.75▼$3.9550-Day Range$2.93▼$4.2352-Week Range$1.83▼$28.03Volume12,350 shsAverage Volume35,667 shsMarket Capitalization$20.38 millionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingHold Company Overview NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period. The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia. Its lead candidate has advanced into mid-stage clinical trials, where the company is evaluating safety, tolerability and efficacy in patients experiencing severe disruptions in their sleep-wake patterns. Preclinical programs are also exploring additional indications in related neurophysiological and metabolic conditions. Founded in 2015, NLS Pharmaceutics has built a research platform that integrates advanced pharmacokinetic modeling with circadian biology to enhance therapeutic outcomes. The company collaborates with academic institutions and sleep-medicine centers in North America and Europe to support patient recruitment and biomarker development. Through these partnerships, NLS Pharmaceutics aims to accelerate proof-of-concept studies and bring innovative treatments to market more efficiently. NLS Pharmaceutics is led by an executive team with extensive experience in drug discovery, clinical development and regulatory affairs. The company’s strategy centers on addressing underserved patient populations and leveraging its circadian platform to expand into new therapeutic areas. By focusing on precise modulation of biological rhythms, NLS Pharmaceutics seeks to deliver differentiated therapies that improve quality of life for patients with chronic sleep and circadian disorders. AI Generated. May Contain Errors. Read More NLS Pharmaceutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreNCEL MarketRank™: NLS Pharmaceutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 343rd out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingNLS Pharmaceutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialNLS Pharmaceutics has a consensus price target of $23.00, representing about 503.7% upside from its current price of $3.81.Amount of Analyst CoverageNLS Pharmaceutics has only been the subject of 2 research reports in the past 90 days.Read more about NLS Pharmaceutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioNLS Pharmaceutics has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.25% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 4.92.Change versus previous monthShort interest in NLS Pharmaceutics has recently decreased by 6.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNLS Pharmaceutics does not currently pay a dividend.Dividend GrowthNLS Pharmaceutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest2 people have searched for NCEL on MarketBeat in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of NLS Pharmaceutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $374,998.00 in company stock, which represents 1.8397% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, NLS Pharmaceutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $374,998.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsNLS Pharmaceutics has minimal institutional ownership at this time.Read more about NLS Pharmaceutics' insider trading history. Receive NCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NCEL Stock News HeadlinesNewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory BoardJuly 8, 2026 | globenewswire.comNewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 DiabetesJuly 1, 2026 | globenewswire.comBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | Awesomely (Ad)NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology PlatformJune 15, 2026 | globenewswire.comNewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 DiabetesMay 27, 2026 | globenewswire.comNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026April 30, 2026 | globenewswire.comNewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceApril 20, 2026 | globenewswire.comNewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium PricingApril 1, 2026 | globenewswire.comSee More Headlines NCEL Stock Analysis - Frequently Asked Questions How have NCEL shares performed this year? NLS Pharmaceutics' stock was trading at $1.90 at the beginning of the year. Since then, NCEL shares have increased by 100.5% and is now trading at $3.81. When did NLS Pharmaceutics' stock split? NLS Pharmaceutics's stock reverse split on the morning of Friday, October 31st 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of NLS Pharmaceutics? Shares of NCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NCEL's financial health is in the Green zone, according to TradeSmith. NCEL has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NCEL Previous SymbolNASDAQ:NLSP CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/APrice Target and Rating Average Price Target for NLS Pharmaceutics$23.00 High Price Target$23.00 Low Price Target$23.00 Potential Upside/Downside+503.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book2.40Miscellaneous Outstanding Shares5,350,000Free Float4,468,000Market Cap$20.38 million OptionableNot Optionable Beta0.93 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:NCEL) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored30-Year market veteran reveals America’s #1 StockMarket veteran Jim Woods has flagged triple-digit gains multiple times in under two months - 151% on Netflix, ...Eagle Publishing | SponsoredNot oil. Not solar. Bigger.The International Energy Agency measured it at 140 times global electricity demand. It runs 24 hours a day, pr...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
